In a report issued on July 2, Rick Wise from Stifel Nicolaus reiterated a Buy rating on Transenterix Inc (NYSE: TRXC), with a price target of $5.50. The company’s shares closed on Tuesday at $3.84.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 13.4% and a 71.7% success rate. Wise covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Boston Scientific Corp, and Baxter International.
Currently, the analyst consensus on Transenterix Inc is a Moderate Buy with an average price target of $4.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.04 and a one-year low of $0.60. Currently, Transenterix Inc has an average volume of 5.8M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. operates as a development stage medical device company. It focuses on research, development and sale of medical device robotics to improve minimally invasive surgery.
Read More on TRXC:
